Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2022 | Losartan | Research

Does Losartan reduce the severity of COVID-19 in hypertensive patients?

Authors: Mohammadreza Mirjalili, Moslem Taheri Soodejani, Mehdi Raadabadi, Ali Dehghani, Fateme Salemi

Published in: BMC Cardiovascular Disorders | Issue 1/2022

Abstract

Background

One of the global problems is to control the coronavirus epidemic, and the role of different medicines is still unknown to policymakers. This study was conducted to evaluate the effects of losartan on the mortality rate of COVID-19 in hypertensive patients.

Methods

The research sample of analytical study included 1458 patients presenting to COVID-19 diagnostic centers in Yazd that were examined in the first six months of 2020. Data were analyzed using descriptive statistics as well as chi-square, Fisher’s exact test, t test, and logistic regression.

Results

Of 1458 subjects that were studied, 280 were hypertensive of whom 179 tested positive for SARS-CoV-2 PCR. The results showed a lower chance of death by more than 5 times in hypertensive patients who used losartan (P = 0.003). Moreover, regarding the effect of losartan on the prevention of COVID-19 in hypertensive patients, it was found that this medicine played a protective role although this relationship was not statistically significant (P = 0.86).

Conclusions

The results showed that losartan reduced the chance of mortality in hypertensive patients. It is recommended that the effect of losartan and other blood pressure medicines on COVID-19 patients be investigated in larger studies as well as laboratory investigations.

Gralinski LE, Menachery VD. Return of the Coronavirus: 2019-nCoV. Viruses. 2020;12(2):135. https://doi.org/10.3390/v12020135.CrossRefPubMedCentral

Alshahrani MS, Sindi A, Alshamsi F, Al-Omari A, El Tahan M, Alahmadi B, et al. Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus. Ann Intensive Care. 2018;8(1):1–10. https://doi.org/10.12659/msm.925364.CrossRef

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes care. 2020;43(7):1382–91. https://doi.org/10.2337/dc20-0598.CrossRefPubMed

Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infection. 2020;80(6):e14–8. https://doi.org/10.1016/j.jinf.2020.03.005.CrossRef

Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239–42. https://doi.org/10.1001/jama.2020.2648.CrossRefPubMed

Puskarich MA, Ingraham NE, Merck LH, Driver BE, Wacker DA, Black LP, et al. Effect of losartan on hospitalized patients with COVID-19-induced lung injury: A randomized clinical trial. medRxiv. 2021. https://doi.org/10.1101/2021.08.25.21262623.

Nejat R, Sadr AS. Are losartan and imatinib effective against SARS-CoV2 pathogenesis? A pathophysiologic-based in silico study. In silico Pharmacol. 2021;9(1):1–22. https://doi.org/10.1007/s40203-020-00058-7.CrossRefPubMed

Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018;19:1–13. https://doi.org/10.1186/s13063-017-2427-0.CrossRef

10.

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L. Dexamethasone in Hospitalized Patients with Covid-19. 2021;384(8):693–704. https://dx.doi.org/10.1056%2FNEJMoa2021436.

11.

Scavone C, Brusco S, Bertini M, Sportiello L, Rafaniello C, Zoccoli A, et al. Current pharmacological treatments for COVID-19: What’s next? Br J Pharmacol. 2020;177(21):4813–24. https://doi.org/10.1111/bph.15072.CrossRefPubMedPubMedCentral

12.

Jazzi AS, Mahnam K, Hejazi SH, Damavandi MS, Sadeghi P, Zeinalian M, et al. Inhibition of viral macrodomain of covid-19 and human trpm2 by losartan. Preprint. 2020. https://doi.org/10.20944/preprints202003.0457.v1.CrossRef

13.

Zeinalian M, Salari-Jazi A, Jannesari A, Khanahmad H. A potential protective role of losartan against coronavirus-induced lung damage. Infection Control Hosp Epidemiol. 2020;41(6):752–3. https://doi.org/10.1017/ice.2020.80.CrossRef

14.

Flacco ME, Martellucci CA, Bravi F, Parruti G, Cappadona R, Mascitelli A, et al. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020;106(19):1519–24. https://doi.org/10.1136/heartjnl-2020-317336.CrossRefPubMed

15.

Wevers BA. Hoek Lvd. Renin–angiotensin system in human coronavirus pathogenesis. Future Virol. 2010;5(2):145–61. https://doi.org/10.2217/fvl.10.4.CrossRefPubMedPubMedCentral

16.

Clarke NE, Turner AJ. Angiotensin-converting enzyme 2: the first decade. Int J Hypertens. 2012;2012. https://doi.org/10.1155/2012/307315.

17.

McIntyre M, Caffe S, Michalak R, Reid J. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol Therap. 1997;74(2):181–94. https://doi.org/10.1016/S0163-7258(97)82002-5.CrossRef

18.

Salama ZA, Sadek A, Abdelhady AM, Darweesh SK, Morsy SA, Esmat G. Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. Hepatob Surg Nutr. 2016;5(3):249.CrossRef

19.

Sellers SL, Milad N, Chan R, Mielnik M, Jermilova U, Huang PL, et al. Inhibition of Marfan Syndrome Aortic Root Dilation by Losartan: Role of Angiotensin II Receptor Type 1–Independent Activation of Endothelial Function. Am J Pathol. 2018;188(3):574–85. https://doi.org/10.1016/j.ajpath.2017.11.006.CrossRefPubMed

20.

Choi JA, Kim J-E, Ju H-h, Lee J, Jee D, Park CK, et al. The effects of losartan on cytomegalovirus infection in human trabecular meshwork cells. Plos one. 2019;14(6):e0218471. https://doi.org/10.1371/journal.pone.0218471.CrossRefPubMedPubMedCentral

21.

Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730. https://dx.doi.org/10.1002%2Fcbic.202000047.CrossRef

22.

Ivanov M, Mihailović-Stanojević N, Grujić Milanović J, Jovović Đ, Marković-Lipkovski J, Ćirović S, et al. Losartan improved antioxidant defense, renal function and structure of postischemic hypertensive kidney. PloS one. 2014;9(5):e96353. https://doi.org/10.1371/journal.pone.0096353.CrossRefPubMedPubMedCentral

23.

Kouhpayeh S, Shariati L, Boshtam M, Rahimmanesh I, Mirian M, Zeinalian M, et al. The molecular story of COVID-19; NAD+ depletion addresses all questions in this infection. 2020. Kouhpayeh, S.; Shariati, L.; Boshtam, M.; Rahimmanesh, I.; Mirian, M.; Zeinalian, M.; Salari-jazi, A.; Khanahmad, N.; Damavandi, M.S.; Sadeghi, P.; Khanahmad, H. The Molecular Story of COVID-19; NAD+ Depletion Addresses All Questions in this Infection. Preprints 2020, 2020030346 https://doi.org/10.20944/preprints202003.0346.v1.

24.

Covid C, Team R, COVID C, Team R, COVID C, Team R, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. Morbidity and mortality weekly report. 2020;69(12):343. https://dx.doi.org/10.15585%2Fmmwr.mm6912e2.

25.

TNCPERE T. Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)-China, 2020. 2020.

26.

Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72. https://doi.org/10.1016/j.cmi.2020.04.012.CrossRefPubMedPubMedCentral

27.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811–8. https://doi.org/10.1001/jamacardio.2020.1017.CrossRefPubMed

28.

Nuzzi V, Merlo M, Specchia C, Lombardi CM, Carubelli V, Iorio A, et al. The prognostic value of serial troponin measurements in patients admitted for COVID-19. ESC Heart Failure. 2021;8(5):3504–11. https://doi.org/10.1002/ehf2.13462.CrossRefPubMedPubMedCentral

29.

Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microb Infect. 2020;9(1):757–60. https://doi.org/10.1080/22221751.2020.1746200.CrossRef

Title: Does Losartan reduce the severity of COVID-19 in hypertensive patients?
Authors: Mohammadreza Mirjalili
Moslem Taheri Soodejani
Mehdi Raadabadi
Ali Dehghani
Fateme Salemi
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Losartan
SARS-CoV-2
COVID-19
Hypertension
Hypertension
Published in: BMC Cardiovascular Disorders / Issue 1/2022
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-022-02548-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does Losartan reduce the severity of COVID-19 in hypertensive patients?

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Impact of estimated glucose disposal rate for identifying prevalent ischemic heart disease: findings from a cross-sectional study

Segmental strain for scar detection in acute myocardial infarcts and in follow-up exams using non-contrast CMR cine sequences

Coronary microcirculation dysfunction evaluated by myocardial contrast echocardiography predicts poor prognosis in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention

Association of ALDH2 rs671 and MTHFR rs1801133 polymorphisms with hypertension among Hakka people in Southern China

Organ damage evaluation in a temperature-controlled circulatory arrest rat model

Occluding morphologically complicated left atrial appendage using the small-umbrella LAmbre device